Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression

被引：48

作者：

Tokuhira, Michihide ^{[1
]}

Saito, Shuntaro ^{[1
,2
]}

Okuyama, Ayumi ^{[3
]}

Suzuki, Katsuya ^{[2
]}

Higashi, Morihiro ^{[4
]}

Momose, Shuji ^{[4
]}

Shimizu, Takayuki ^{[5
]}

Mori, Takehiko ^{[5
]}

Anan-Nemoto, Tomoe ^{[1
]}

Amano, Koichi ^{[3
]}

Okamoto, Shinichiro ^{[5
]}

Takeuchi, Tsutomu ^{[2
]}

Tamaru, Jun-Ichi ^{[4
]}

Kizaki, Masahiro ^{[1
]}

机构：

[1] Saitama Med Univ, Dept Hematol, Saitama Med Ctr, 1981 Kamoda, Kawagoe, Saitama 3508550, Japan

[2] Keio Univ, Div Rheumatol, Dept Med, Sch Med, Tokyo, Japan

[3] Saitama Med Univ, Dept Rheumatol & Clin Immunol, Saitama Med Ctr, Kawagoe, Saitama, Japan

[4] Saitama Med Univ, Dept Pathol, Saitama Med Ctr, Kawagoe, Saitama, Japan

[5] Keio Univ, Div Hematol, Dept Med, Sch Med, Tokyo, Japan

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 05期

关键词：

Methotrexate; lymphoproliferative disorders; autoimmune diseases; rheumatoid arthritis; regression; EPSTEIN-BARR-VIRUS; RHEUMATOID-ARTHRITIS PATIENTS; B-CELL LYMPHOMA; JAPANESE PATIENTS; DISEASE; PATIENT; ASSOCIATION; WITHDRAWAL; INFECTION; THERAPY;

D O I：

10.1080/10428194.2017.1369073

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although recent accumulative data reveal the clinicopathogenesis of regression in methotrexate-induced lymphoproliferative disorders (MTX-LPDs), the precise understanding including this category remains controversial. In this study, we analyzed 62 patients with MTX-LPD. Forty-three patients showed regression (Reg group), with high rates of Hodgkin lymphoma (HL) and LPD (90 and 88%, respectively). Among the 43 patients of the Reg group, 14 patients (33%) relapsed. The median duration before relapse in the Reg group was 10.6 months. Although the difference of OS between the Reg and Non-Reg groups was not significantly different, relapse-free patients in the Reg group had a superior overall survival (OS). MTX duration had a significant impact on Epstein-Barr virus (EBV) infection (p=.00131). Furthermore, EBV infection was significantly related to clinical manifestations, including spleen invasion, in the regression phenomenon. Some human leukocyte antigens (HLA) alleles might affect MTX-LPD development via EBV infection, although A*2402 and DRB1*0405 might be affected as fundamental factors.

引用

页码：1143 / 1152

页数：10

共 30 条

[1] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[2] Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis [J].

Baecklund, E ;

Iliadou, A ;

Askling, J ;

Ekborn, A ;

Backlin, C ;

Granath, F ;

Catrina, AT ;

Rosenquist, R ;

Feltelius, N ;

Sundström, C ;

Klareskog, L .

ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :692-701

[3] Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis - Accurate quantification using real-time polymerase chain reaction [J].

Balandraud, N ;

Meynard, JB ;

Auger, I ;

Sovran, H ;

Mugnier, B ;

Reviron, D ;

Roudier, J ;

Roudier, C .

ARTHRITIS AND RHEUMATISM, 2003, 48 (05) :1223-1228

[4] Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis [J].

Furukawa, Hiroshi ;

Oka, Shomi ;

Shimada, Kota ;

Hashimoto, Atsushi ;

Tohma, Shigeto .

JOURNAL OF HUMAN GENETICS, 2015, 60 (11) :691-696

[5]

Gaulard P, 2008, WHO Classification Tumours Haematopoietic Lymphoid Tissues, P350

[6] Incidence of Malignancy and the Risk of Lymphoma in Japanese Patients with Rheumatoid Arthritis Compared to the General Population [J].

Hashimoto, Atsushi ;

Chiba, Noriyuki ;

Tsuno, Hirotaka ;

Komiya, Akiko ;

Furukawa, Hiroshi ;

Matsui, Toshihiro ;

Nishino, Jinju ;

Tohma, Shigeto .

JOURNAL OF RHEUMATOLOGY, 2015, 42 (04) :564-571

[7] Immunomodulator agent-related lymphoproliferative disorders [J].

Hasserjian, Robert P. ;

Chen, Steve ;

Perkins, Sherrie L. ;

de Leval, Laurence ;

Kinney, Marsha C. ;

Barry, Todd S. ;

Said, Jonathan ;

Lim, Megan S. ;

Finn, William G. ;

Medeiros, L. Jeffrey ;

Harris, Nancy L. ;

O'Malley, Dennis P. .

MODERN PATHOLOGY, 2009, 22 (12) :1532-1540

[8] Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis [J].

Horie, N. ;

Kawano, R. ;

Kaneko, T. ;

Shimoyama, T. .

AUSTRALIAN DENTAL JOURNAL, 2015, 60 (03) :408-411

[9] Lymphoproliferative disorders in autoimmune diseases in Japan: Analysis of clinicopathological features and Epstein-Barr virus infection [J].

Hoshida, Y ;

Tomita, Y ;

Dong, ZM ;

Yamauchi, A ;

Nakatsuka, S ;

Kurasono, Y ;

Arima, Y ;

Tsudo, M ;

Shintaku, M ;

Aozasa, K .

INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (03) :443-449

[10] Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression [J].

Ichikawa, Ayako ;

Arakawa, Fumiko ;

Kiyasu, Junichi ;

Sato, Kensaku ;

Miyoshi, Hiroaki ;

Niino, Daisuke ;

Kimura, Yoshizo ;

Takeuchi, Masanori ;

Yoshida, Maki ;

Ishibashi, Yukinao ;

Nakashima, Shinji ;

Sugita, Yasuo ;

Miura, Osamu ;

Ohshima, Koichi .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 91 (01) :20-28

← 1 2 3 →